The Vital Difference: Independent Community Pharmacies vs. Chain Pharmacies

The Vital Difference: Independent Community Pharmacies vs. Chain Pharmacies

Introduction In today’s fast-paced world, pharmacies play a vital role in granting people access to fundamental medicines and health services. There are two primary categories of pharmacies: independent community pharmacies and chain pharmacies. Despite serving as crucial healthcare facilities, they differ greatly in treating patients, offering customized services, and incorporating with the community. In this…

Meet our CEO at PharmSci360 in Florida!

Join our session RxE2 CEO, Gerald Finken, will be taking part in a panel titled: “The Integration of Clinical Trials and Clinical Care: A Revolution in the Participant and Sponsor Experience or an Implementation Nightmare? Or Both?” When & Where Monday, October 23, 2023 | 7:00 AM – 9:00 AM ET | Location:308 AB West Meet…

Imagine where your Clinical Trials can go…

Imagine where your Clinical Trials can go…

While RxE2 continues promoting the practice of pharmacy and community-based pharmacists in clinical trials in the United States, the European Association of Hospital Pharmacies (EAHP) is encouraging the involvement of hospital pharmacists in European clinical trials. RxE2 applauds the EAHP for taking a position on clinical trials and their recognition of the valuable contributions pharmacists…

Meet RxE2 at GCSG2023!

Meet us at GCSG 2023!

RxE2 is disrupting the clinical supply chain to improve quality and eliminate waste – Meet us at #GCSG2023! Current supply chain logistics provide ample opportunity for risk and waste. What if we eliminate that? Led by Gerald E. Finken, the inventor of On-Demand Packaging & Labeling, RxE2 is de-risking the process by eliminating unnecessary steps for truly patient centric…

Diversity in Clinical Trials

Diversity in Clinical Trials – How to stop talking about it and actually do it

Diversity in Clinical Trials – Background The Federal Drug Administration (FDA) issued non-compulsory guidance on clinical trial diversity to encourage diverse populations in clinical trials and improve the applicability of clinical trial results. The guidance recommends diverse clinical trial populations to better understand the safety and effectiveness of medical products across race, ethnicity, and gender.…